Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 11;10(1):e001878. doi: 10.1136/bmjresp-2023-001878

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

CD8+KLRB1+ T cells decreased in advanced lung adenocarcinoma (LUAD). (A) Uniform manifold approximation and projection (UMAP) plot of subpopulations of CD8+ T cells. (B) Dot plot showing expression levels of specific markers in each CD8+ T subpopulation. (C) The partition-based graph abstraction (PAGA) embedding plot showing the trajectory inference of CD8+ T subpopulations. (D) PAGA graph showing the distribution of CD8+ T subpopulations. The width of line representing the connectivity adjacency between clusters. (E) Pseudotime plot of CD8+ T subpopulations. (F) Box plot showing the proportion of three CD8+KLRB1+ T cells in three stages of LUAD. (G) Kaplan-Meier survival analysis for two groups defined by patients in The Cancer Genome Atlas (TCGA)-LUAD cohort with high/low expression KLRB1. The sample numbers for each group are shown in brackets. Statistical significance is determined by log-rank test. (H) Gene Ontology pathway enrichment analysis of differential gene expression (log2 fold change (FC) ≥0.25 or ≤0.25 and FDR ≤0.05) between CD8+KLRB1+ T cells and the rest of CD8+ T cells. (I) Gene set enrichment analysis for the ranked gene lists according to FCs of gene expression in the CD8+KLRB1+ T cells compared with the rest of CD8+ T cells.